The American College of Medical Genetics and Genomics Foundation for Genetic and Genomic Medicine grants its Next Generation Fellowship Awards to promising early-career professionals in a range of medical genetics and genomics specialties. The awards were presented at the 2022 ACMG Clinical Genetics Meeting.
The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.
The country’s Ministry of Health has issued infringement notices to two ophthalmologist for seeing patients while unvaccinated.
The MIRA-3 Phase 3 FDA Registration trial for Nyxol met its primary endpoint with 58% of treated subjects returning to baseline pupil diameter at 90 minutes compared to 6% of placebo subjects.
The company’s iCare HOME2 self-tonometer allows patients to collect real-world IOP data at any time.
Assembling a team of experts is key for diagnosis, treatment
Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject in lowering IOP as a standalone treatment option without concomitant cataract surgery.
The EVO/EVO+ Visian Implantable Collamer Lens provides visual freedom independent of contact lenses and glasses.
Mark Packer, MD, shares his perspective on the relationship between ICL implantation or LASIK and retinal detachment.
Assessing cornea status can aid early recognition of disease-related changes
The San Francisco-based company also announces that Raj K. Maturi, MD, is the first PI in the network.
Vanderbilt’s David Calkins, PhD, was honored with the 2022 President’s Award, presented by the Glaucoma Research Foundation, at the Glaucoma 360 Annual Gala last month.
Investigators theorize that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.
Sponsored Content
Lower doses vs higher ones are equally effective for treating disease
Investigators have questioned the potential for the vascular density to be a biomarker for microvascular abnormalities following COVID-19 and found that longitudinal studies are needed to determine this.
According to the company, VVN001 demonstrated clinical and statistical superiority over vehicle in reducing total and sub-regional corneal fluorescein staining scores.
A team of investigators at the Okinawa Institute of Science and Technology Graduate University in Japan have identified a gene necessary for the survival of retinal ganglion cells – a class of neurons located in the retina that are critical for vision.
The company notes that its clinical trial of the light delivery system meets the primary efficacy endpoint, and can offer hope to patients with dry AMD who are experiencing vision loss and currently have limited treatment options.
The company has dosed the first patients in a Phase 3 trial evaluating the safety and efficacy of Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.
Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.
Provides safe, effective injection to target choroidal, retinal tissues
Jorge Calzada, MD, shares his use of MicroPulse laser technology to combat central serous retinopathy (CSR).
According to a team of investigators at University of California, Berkeley, tests of the drug Antabuse could prove the role of hyperactive retinal cells in blindness, potentially leading to better therapies.
Drug is prescribed as adjunctive therapy for those with glaucoma
Investigators find that hybrid cells could be a potential therapeutic strategy to treat retinal damage and visual impairment.
Gary Jerkins, MD, a Nashville physician who founded SeaStar Kids in 2010 to help disadvantaged Ukrainian youth, has made 47 trips to Ukraine since 1996 and has hope for its future.
"Tell Me Your Secrets" is the theme of the virtual April 2 event, which is expected to build on the foundation established during the first program held last fall.
A team of investigators has found that nomacopan, a recombinant biologic derived from blood-feeding ticks, may be an option for the treatment of allergic eye disease due to its ability to down-regulate the LTB4/C5 pathways in experimental allergy conjunctivitis.
Researchers from the Department of Ophthalmology at the University Hospital Bonn and Deutsches Zentrum für Neurodegenerative Erkrankungen suggest that assessments of the eye’s retina could help to detect a loss of brain substance, i. e. “brain atrophy.” The findings are based on data from the Rhineland Study.
